Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Making moves

<< Previous

Bullboard Posts

Next >>

Comment by Straylighton Dec 29, 2020 11:09am

210 Views

Post# 32191194

RE:RE:Making moves

I believe so. There were notices in my trading platform that today is the last day for trades to clear in the 2020 year so I guess it was the last chance for folks to tax-loss sell. That was probably done first thing this morning hence the move north.

Glad to have been buying the last while.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China